[Specific immunotherapy in allergies--evaluation of current status]

Area of Science:

• Allergy and Immunology
• Immunotherapy Research
• Clinical Allergy Management

Background:

• Specific immunotherapy is the primary treatment for inhalant allergies.
• Several variables influence immunotherapy efficacy, including administration route, dosage, allergen quality, and patient factors.
• Antihistamine premedication is essential for minimizing side effects during treatment.

Purpose of the Study:

• To highlight the efficacy of specific immunotherapy for inhalant allergies.
• To outline key considerations for optimizing immunotherapy protocols.
• To identify contraindications for specific immunotherapy.

Main Methods:

• Review of established protocols for specific immunotherapy.
• Analysis of factors influencing treatment outcomes.
• Identification of patient-specific variables and contraindications.

Main Results:

• Specific immunotherapy demonstrates high efficacy, achieving symptom reduction in nearly 90% of patients.
• A 50-100% reduction in allergy symptoms is commonly observed.
• Histamine intolerance is identified as a contraindication.

Conclusions:

• Specific immunotherapy is a highly effective treatment for inhalant allergies.
• Optimizing immunotherapy requires careful attention to application route, dose, allergen selection, and patient characteristics.
• Patient screening for histamine intolerance is necessary prior to initiating immunotherapy.